Business Development


Autonomous University of Barcelona

Ability Pharmaceuticals has a research collaboration with Dr. José Miguel Lizcano's laboratory at the Department of Biochemisty, Faculty of Medicine of the Autonomous University of Barcelona, in Bellaterra.

Vall d'Hebron Institut d’Oncologia

Ability Pharmaceuticals Phase II clinical studies performed at the Department of Oncology at the Vall d'Hebron University Hospital. Dr. Ana Oaknin is the Principal Investigator.

SciClone Pharmaceuticals, Inc.

In April 2016, AbilityPharma signed a territorial license agreement for ABTL0812 with the NASDAQ US company SciClone Pharmaceuticals to develop and market the product in Greater China, with upfront and milestone payments over $ 20 M


Ability Pharmaceuticals has research collaborations with the Area of Molecular and Translational Oncology of the IDIBAPS (Institut d'Investigacions Biomèdiques August Pi i Sunyer), associated with the Hospital Clinic de Barcelona and the University of Barcelona. The Area is led by Dr. Pere Gascon.

Hospital Clínic de Barcelona

Ability Pharmaceuticals conducted the Phase I/Ib clinical trials at the Medical Oncology Service and at the Clinical Institute of Hemato-Oncological Diseases y (ICMHO) of the Hospital Clinic de Barcelona. Dr. Laura Vidal was the Principal Investigator.

Institut Catala d'Oncologia

Ability Pharmaceuticals perform the phase II clinical studies in the Catalan Institute of Oncology (ICO) in the centers of L'Hospitalet, Girona and Badalona. Dr. Ernest Nadal, Dr. Joaquim Bosch and Dr. Teresa Moran are the principal investigators, respectively.

University of Girona

Ability Pharmaceuticals has a research collaboration with Dr. Teresa Puig's laboratory at the Department of Molecular Oncology, Faculty of Medicine of the University of Girona (Catalonia).

Universitat de Lleida

Ability Pharmaceuticals has a research collaboration with Dr. Xavier Matias-Guiu, head of pathological anatomy at Bellivtge Hosptial and Arnau de Vilanova Hospital and director of Biomedical Research Institute of Lleida (IRB). The collaboration also includes Dra. Nuria Eritja, head of the pathological laboratory and oncology group at IRB, and Dra. Eva Colàs, principal investigator currently in Vall d’Hebron Institut de Recerca (VHIR), Barcelona.

Vall d'Hebron Research Institute

Ability Pharmaceuticals has a research collaboration with Dr. Miguel Segura's laboratory of the Tranlational Research in Pediatric Carcer Group of the Vall d’Hebron Institut de Recerca (VHIR), Barcelona.


Medalchemy has developed the synthetic routes of the drug candidates being developed by Ability Pharmaceuticals and is proceeding to the escalation of their production.
Medalchemy is base at the Science Park of the University of Alicante/Alacant.

European Network for the Study of Cholangiocarcinoma

We belong to the ENS-CCA, a group of active researchers with a broad interest in cholangiocarcinoma clinical area, which has significantly contributed to the study into the pathophysiology of the biliary tree and development/onset of cholangiocarcinoma, and pursuing basic, translational and clinical research in an effort to identify treatment options with successful outcome for this type of cancer. 



Press Release

AbilityPharma receives a 1.6 million euro grant from the FDA and opens a crowdfunding campaign in Capital Cell + info

Press Release


Press Release

AbilityPharma publishes full characterization of mechanism of action of ABTL0812, a Phase II clinical inducer of cytotoxic autophagy in cancer cells, in Autophagy journal + info

Press Release

AbilityPharma awarded €5 million from the Horizon Europe EIC Accelerator Pilot Program to conduct a Phase 2b clinical trial with ABTL0812 in patients with advanced pancreatic cancer + info

Press Release

AbilityPharma rises € 3.5 million in a financing round to complete the current oncologic phase 2 clinical trial and license ABTL0812 to an international pharmaceutical company + info

Press Release

Ability Pharmaceuticals Announces the Presentation of the First Results of ABTL0812 as First Line in Patients with Endometrial or Lung Cancer at 2019 ASCO Annual Meeting + info

Press Release

Ability Pharmaceuticals Announces the Approval in China of a Clinical Study in Pancreatic Cancer with ABTL0812 + info

Press Release

Ability Pharmaceuticals is attending the BIOMED EVENT® by INVEST SECURITIES and the Cholangiocarcinoma Foundation Annual Conference + info

Press Release

AbilityPharma ha superado el millón de euros en la ronda de crowdfunding que abrió el pasado mes de septiembre + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police